可能的肿瘤治疗剂——^(188)Re-硫化铼混悬液的初步研究  

PRELIMINARY STUDY ON A POTENTIAL TUMOR RADIOTHERAPY AGENT 188 Re RHENIUM SULFIDE SUSPENSION

作　　者：于俊峰[1] 闵小锋[1] 张炯[1] 郭子丽[1] 汪勇先[1] 

机构地区：[1]中国科学院上海原子核研究所

出　　处：《同位素》1999年第2期74-78,共5页Journal of Isotopes

摘　　要：１８８Ｒｅ－硫化铼混悬液是由Ｎａ２Ｓ２Ｏ３和ＫＲｅＯ４以及Ｎａ１８８ＲｅＯ４在酸性溶液中反应制得１８８Ｒｅ－硫化铼沉淀，加入ＰＶＰ超声５ｍｉｎ后获得。其放化产率＞９６％，体外稳定性研究表明３ｄ内大于９９％的１８８Ｒｅ以硫化铼的形式存在，颗粒度主要为１～５μｍ。采取瘤内直接注射法将混悬液直接注入荷瘤鼠肿瘤（Ｓ－１８０肉瘤）内，放射性在瘤内３ｄ的保持率约为９０％。用生理盐水或非放硫化铼混悬液作对照组，结果表明１８８Ｒｅ－硫化铼对肿瘤抑制率达９６％。Re rhenium sulfide suspension is formed by acid reduction of Na 2S 2O 3 in the presence of KReO 4 including Na 188 ReO 4. The radiochemical yield is more than 96%. The in vitro stability studies reveal that more than 99% of 188 Re remains in sulfide form in 3 days. The major particle size is 1～5 μm. 188 Re rhenium sulfide suspension is injected into tumors of mice and the tumor b ea ring mice are killed in certain interval. The results of the biodistribution stu dy show that the mean retention percentages of 188 Re in tumors are about 90% in 3 days. Compared with the control which is injected the inactive r henium sulfide suspension or normal saline, the tumor inhibiting ratio by intra tumor injection of 188 Re rhenium sulfide suspension is about 96% .

关 键 词：混悬液 生物分布 肿瘤抑制率 镭-硫化铼 

分 类 号：R730.55[医药卫生—肿瘤] R817.9[医药卫生—临床医学]